These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 1683612

  • 1. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade.
    Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G.
    Circulation; 1991 Dec; 84(6 Suppl):VI72-7. PubMed ID: 1683612
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S, Handa S, Abe S, Takahashi E, Kawai Y, Watanabe K, Yoshikawa T, Hori S, Ikeda Y.
    J Cardiol; 1993 Dec; 23(4):335-41. PubMed ID: 8064582
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment.
    Burris JF.
    Arch Intern Med; 1993 Sep 27; 153(18):2085-92. PubMed ID: 8104394
    [Abstract] [Full Text] [Related]

  • 6. Beta-blockers, plasma lipids, and coronary heart disease.
    Cruickshank JM.
    Circulation; 1990 Sep 27; 82(3 Suppl):II60-5. PubMed ID: 1975524
    [Abstract] [Full Text] [Related]

  • 7. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
    Miyamoto S, Kawano H, Takazoe K, Soejima H, Sakamoto T, Hokamaki J, Yoshimura M, Nakamura H, Yodoi J, Ogawa H.
    Thromb Res; 2004 Sep 27; 113(6):345-51. PubMed ID: 15226088
    [Abstract] [Full Text] [Related]

  • 8. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
    Winther K, Gleerup G, Hedner T.
    J Cardiovasc Pharmacol; 1991 Sep 27; 18 Suppl 9():S41-4. PubMed ID: 1725542
    [Abstract] [Full Text] [Related]

  • 9. Advances in clinical fibrinolysis.
    Hessel LW, Kluft C.
    Clin Haematol; 1986 May 27; 15(2):443-63. PubMed ID: 2942332
    [Abstract] [Full Text] [Related]

  • 10. Are we misunderstanding beta-blockers.
    Cruickshank JM.
    Int J Cardiol; 2007 Aug 09; 120(1):10-27. PubMed ID: 17433471
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive drugs and fibrinolytic function.
    Fogari R, Zoppi A.
    Am J Hypertens; 2006 Dec 09; 19(12):1293-9. PubMed ID: 17161777
    [Abstract] [Full Text] [Related]

  • 12. Activation of the fibrinolytic system in patients with coronary artery disease and hyperfibrinogenemia.
    Stein D, Heins M, Schoebel FC, Pels K, Jax TW, Stiegler H, Reinauer H, Strauer BE, Leschke M.
    Thromb Haemost; 1997 May 09; 77(5):970-4. PubMed ID: 9184412
    [Abstract] [Full Text] [Related]

  • 13. Fibrinolytic activity in coronary heart disease.
    Yao SK, Chen ZJ, Tao SQ.
    Chin Med J (Engl); 1989 Sep 09; 102(9):660-3. PubMed ID: 2517077
    [Abstract] [Full Text] [Related]

  • 14. Pharmacology of beta-blockers: classical aspects and recent developments.
    Haeusler G.
    J Cardiovasc Pharmacol; 1990 Sep 09; 16 Suppl 5():S1-9. PubMed ID: 11527109
    [Abstract] [Full Text] [Related]

  • 15. Beta-blockers in hypertensive and coronary heart disease.
    Goldstein S.
    Arch Intern Med; 1996 Jun 24; 156(12):1267-76. PubMed ID: 8651834
    [Abstract] [Full Text] [Related]

  • 16. Beta-blockers in hypertension.
    Hansson L.
    J Hypertens Suppl; 1987 Aug 24; 5(3):S61-7. PubMed ID: 2889813
    [Abstract] [Full Text] [Related]

  • 17. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ, Schalekamp MA.
    Postgrad Med J; 1983 Aug 24; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [Abstract] [Full Text] [Related]

  • 18. Prevention of sudden death using beta-blockers. Review of possible contributory actions.
    Olsson G, Rydén L.
    Circulation; 1991 Dec 24; 84(6 Suppl):VI33-7. PubMed ID: 1683608
    [Abstract] [Full Text] [Related]

  • 19. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 24; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 20. Abnormalities of fibrinolysis in essential hypertension.
    Ettenger MM, MacCarthy EP, Glas-Greenwalt P, Clyne DH, Pollak VE.
    J Hypertens Suppl; 1984 Dec 24; 2(3):S175-8. PubMed ID: 6242555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.